Atabecestat

Generic Name: Atabecestat

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₄FN_₅OS

CAS Number: 1200493-78-2

Unique Ingredient Identifier: 2834W8D6GK

Background: Atabecestat is under investigation in clinical trial NCT02211079 (A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Remembering Bruce Albala, 70, Leader in BACE Inhibitor Development

Bruce Albala, a key figure in Alzheimer's disease drug development, passed away during his 40th wedding anniversary in Greece. Known for his work on β-secretase inhibitors, Albala led Eisai's BACE program, guiding elenbecestat through Phase 3 trials. Despite elenbecestat's limited success, Albala's pragmatic approach and advocacy for safer BACE inhibitor doses were highly regarded. He transitioned to academia in 2019, focusing on improving AD clinical trial efficiency.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy